AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30570356 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation (RMN)
Number of subjects: 70
Study 30570356 — intervention group
Group type: COMPARATOR
Intervention: Manually guided catheter ablation (MAN)
Number of subjects: 70
Study 27809637 — intervention group
Group type: EXPERIMENTAL
Intervention: BBT (anthocyanin-rich black soybean testa extracts), 2.5 g/d
Number of subjects: 63
Study 27809637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch), 2.5 g/d
Number of subjects: 63
Study 24902398 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% arginine calcium carbonate (CaCO3) desensitizing paste
Number of subjects: 303
Study 24902398 — intervention group
Group type: COMPARATOR
Intervention: 5% potassium nitrate (KNO3) toothpaste
Number of subjects: 303
Study 22696266 — intervention group
Group type: EXPERIMENTAL
Intervention: KN38-7271 high-dose (1000 μg)
Number of subjects: 97
Study 22696266 — intervention group
Group type: EXPERIMENTAL
Intervention: KN38-7271 low-dose (500 μg)
Number of subjects: 97
Study 22696266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 22696266 — intervention group
Group type: EXPERIMENTAL
Intervention: KN38-7271 (both doses)
Number of subjects: 97
Study 20683847 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b (1.5 μg/kg/week) plus RBV (800‐1,400 mg/day) for 48 weeks
Number of subjects: 1428
Study 20683847 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b (1.5 μg/kg/week) plus RBV (800‐1,400 mg/day) for 72 weeks
Number of subjects: 1428
Study 20683847 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN alfa‐2b plus RBV for 72 weeks
Number of subjects: 1428
Study 20683847 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN alfa‐2b plus RBV for 48 weeks
Number of subjects: 1428
Study 18615370 — intervention group
Group type: COMPARATOR
Intervention: Transvenous LV-lead placement
Number of subjects: 80
Study 18615370 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial LV-lead placement
Number of subjects: 80
Study 18615370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study 19578239 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 2857
Study 16393219 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna (24 tablets of 12 mg, divided into two doses at 1 p.m. and 9 p.m.)
Number of subjects: 283
Study 16393219 — intervention group
Group type: COMPARATOR
Intervention: PEG-ES (4-L standard solution)
Number of subjects: 283
Study 12482664 — intervention group
Group type: EXPERIMENTAL
Intervention: BBG2Na vaccine
Number of subjects: 0
Study 12482664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9773734 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg q.i.d. (n=105)
Number of subjects: 269
Study 9773734 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=103)
Number of subjects: 269
Study 7921758 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral low-dose cyclophosphamide (CY) after failure of a monthly pulse regimen
Number of subjects: 4
Study 7921758 — intervention group
Group type: COMPARATOR
Intervention: Monthly pulse regimen of cyclophosphamide (CY)
Number of subjects: 4
Study 3078575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral whole cell anti-ETEC vaccine (approx. 3 X 10(10) vaccine cells)
Number of subjects: 19
Study 3078575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11483077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (treated)
Number of subjects: 255
Study 11483077 — intervention group
Group type: COMPARATOR
Intervention: No cryotherapy (control)
Number of subjects: 255
Study 31515880 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) during the general consent process; 90 physicians (88%) engaged in SDM
Number of subjects: 124
Study 31515880 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of end of life issues during consent; 63 physicians (62%)
Number of subjects: 124
Study 31515880 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of existing SDM tools; 44 physicians (43%) used an SDM tool, with Colorado SDM tool being the most common (39; 89%)
Number of subjects: 124
Study 31515880 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of sex-based differences in perceptions related to ICD implantation; 64 physicians (63%) unaware
Number of subjects: 124
Study 31515880 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of race-based differences in perceptions related to ICD implantation; 63 physicians (62%) unaware
Number of subjects: 124
Study 30343311 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS patients
Number of subjects: 80
Study 30343311 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight PCOS patients
Number of subjects: 80
Study 30343311 — intervention group
Group type: COMPARATOR
Intervention: Overweight PCOS patients
Number of subjects: 80
Study 30343311 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study 27251407 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous running
Number of subjects: 22
Study 27251407 — intervention group
Group type: COMPARATOR
Intervention: Vigorous cycling
Number of subjects: 22
Study 27251407 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 22
Study 27251407 — intervention group
Group type: COMPARATOR
Intervention: Control (30 min post-exercise)
Number of subjects: 22
Study 27251407 — intervention group
Group type: COMPARATOR
Intervention: Cartilage thickness
Number of subjects: 22
Study 25549482 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic dose adjusted based on intra-abdominal pressure (IAP)
Number of subjects: 170
Study 25549482 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic dose not adjusted based on IAP
Number of subjects: 170
Study 23017069 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week balance training regime (1-hour training, three times per week)
Number of subjects: 80
Study 20420960 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education programme once a week for 4 weeks, followed by a self‐executed home‐based exercise programme
Number of subjects: 50
Study 20420960 — intervention group
Group type: COMPARATOR
Intervention: Brief course in short‐wave diathermy treatment
Number of subjects: 50
Study 18092565 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention for ASIA A patients with initial SBP < 90 mmHg
Number of subjects: 577
Study 18092565 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention for ASIA A patients with initial SBP >= 90 mmHg
Number of subjects: 577
Study 18092565 — intervention group
Group type: COMPARATOR
Intervention: Comparison of time to surgical intervention based on SBP for ASIA A
Number of subjects: 577
Study 18092565 — intervention group
Group type: COMPARATOR
Intervention: Neurogenic shock presence
Number of subjects: 577
Study 16150205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides tablet (TGT)
Number of subjects: 94
Study 16150205 — intervention group
Group type: COMPARATOR
Intervention: Radix Tripterygium hypoglaucum tablet (THT)
Number of subjects: 94
Study 11819002 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 60
Study 11819002 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ET)
Number of subjects: 60
Study 10517046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant, human brain‐derived neurotrophic factor (rhBDNF)
Number of subjects: 1
Study 10517046 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision of the catheter
Number of subjects: 1
Study 7489345 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 MU lymphoblastoid interferon
Number of subjects: 90
Study 7489345 — intervention group
Group type: COMPARATOR
Intervention: 5 MU lymphoblastoid interferon
Number of subjects: 90
Study 7489345 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 10 MU and 5 MU lymphoblastoid interferon
Number of subjects: 90
Study 7489345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained responders (10 MU and 5 MU)
Number of subjects: 90
Study 7489345 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated liver biopsies (sustained responders)
Number of subjects: 90
Study 2161436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen applied to trunk
Number of subjects: 27
Study 2161436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen applied to legs
Number of subjects: 27
Study 2161436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen applied to entire body
Number of subjects: 27
Study 2161436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen applied to head and neck
Number of subjects: 27
Study 2161436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen applied to arms
Number of subjects: 27
Study 2161436 — intervention group
Group type: COMPARATOR
Intervention: Whole body application of sunscreen
Number of subjects: 27
Study 355183 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 21657 (3 x 300 mg for 6 weeks)
Number of subjects: 40
Study 355183 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 x 1 dragee for 6 weeks)
Number of subjects: 40
Study 355183 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 21657
Number of subjects: 40
Study 355183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31935609 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential density (RD) in tertiles
Number of subjects: 1568
Study 31519391 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine fluoroscopy (Group 1, n: 58)
Number of subjects: 125
Study 31519391 — intervention group
Group type: COMPARATOR
Intervention: No fluoroscopy (Group 2, n: 67)
Number of subjects: 125
Study 28299762 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Supine
Number of subjects: 44
Study 28299762 — intervention group
Group type: COMPARATOR
Intervention: Semi Supine
Number of subjects: 44
Study 26393536 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-frame 21.1-megapixel sensor
Number of subjects: 20
Study 26393536 — intervention group
Group type: COMPARATOR
Intervention: Half-frame 18.0-megapixel sensor
Number of subjects: 20
Study 26393536 — intervention group
Group type: COMPARATOR
Intervention: Compact 10.4-megapixel sensor
Number of subjects: 20
Study 25167350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized bone allograft mixed with platelet growth factors (experimental group)
Number of subjects: 16
Study 25167350 — intervention group
Group type: COMPARATOR
Intervention: Lyophilized bone allograft alone (control group)
Number of subjects: 16
Study 22325129 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on Youth in the Caribbean (FOYC) intervention in grade 6 as part of a randomized trial
Number of subjects: 1997
Study 22325129 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on Youth in the Caribbean (FOYC) intervention as part of the regular school curriculum but outside of the trial
Number of subjects: 1997
Study 22325129 — intervention group
Group type: COMPARATOR
Intervention: Control condition as part of the trial
Number of subjects: 1997
Study 22325129 — intervention group
Group type: COMPARATOR
Intervention: Control condition as part of the school curriculum but outside of the trial
Number of subjects: 1997
Study 22325129 — intervention group
Group type: COMPARATOR
Intervention: Naive controls (not enrolled in a school receiving FOYC or the control condition)
Number of subjects: 1997
Study 19642992 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint reminiscence groups held weekly for twelve consecutive weeks, followed by monthly maintenance sessions for a further seven months
Number of subjects: 400
Study 19642992 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 400
Study 17049992 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol (oral administration) in addition to standard medical treatment for 3 weeks
Number of subjects: 60
Study 17049992 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (control group) for 3 weeks
Number of subjects: 60
Study 15896101 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 300
Study 15796853 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafting of dermal template (allogeneic acellular dermal matrix) with razor thin autoskin
Number of subjects: 20
Study 15796853 — intervention group
Group type: COMPARATOR
Intervention: Grafting of razor thin autoskin only
Number of subjects: 20
Study 11520089 — intervention group
Group type: EXPERIMENTAL
Intervention: Aboral pouch construction
Number of subjects: 46
Study 11520089 — intervention group
Group type: COMPARATOR
Intervention: Simple Roux-en-Y reconstruction
Number of subjects: 46
Study 9883544 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage approach to account for measurement error in surrogate markers
Number of subjects: 0
Study 9883544 — intervention group
Group type: COMPARATOR
Intervention: Naive method using observed marker values in the Cox model
Number of subjects: 0
Study 7933268 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeded polytetrafluoroethylene grafts
Number of subjects: 119
Study 7933268 — intervention group
Group type: COMPARATOR
Intervention: Autologous vein grafts
Number of subjects: 119
Study 2893189 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 fish-oil capsules ('MaxEPA') daily
Number of subjects: 28
Study 2893189 — intervention group
Group type: COMPARATOR
Intervention: 10 placebo capsules (olive oil) daily
Number of subjects: 28
Study 31102045 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Silorane (silorane-based)
Number of subjects: 18
Study 31102045 — intervention group
Group type: EXPERIMENTAL
Intervention: Kalore (methacrylate-based)
Number of subjects: 18
Study 31102045 — intervention group
Group type: COMPARATOR
Intervention: Er,Cr:YSGG laser preparation
Number of subjects: 18
Study 31102045 — intervention group
Group type: COMPARATOR
Intervention: Conventional diamond bur preparation
Number of subjects: 18
Study 30253691 — intervention group
Group type: EXPERIMENTAL
Intervention: mWellcare intervention (mHealth system with integrated management of chronic conditions, evidence-based clinical decision support, longitudinal health data, and automated short-messaging service)
Number of subjects: 631
Study 30253691 — intervention group
Group type: EXPERIMENTAL
Intervention: mWellcare intervention
Number of subjects: 631
Study 28156007 — intervention group
Group type: EXPERIMENTAL
Intervention: DFT+
Number of subjects: 63
Study 28156007 — intervention group
Group type: COMPARATOR
Intervention: DFT-
Number of subjects: 63
Study 25148765 — intervention group
Group type: EXPERIMENTAL
Intervention: YKP10811 10 mg
Number of subjects: 55
Study 25148765 — intervention group
Group type: EXPERIMENTAL
Intervention: YKP10811 20 mg
Number of subjects: 55
Study 25148765 — intervention group
Group type: EXPERIMENTAL
Intervention: YKP10811 30 mg
Number of subjects: 55
Study 25148765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 24035957 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg) with methadone (40-120 mg)
Number of subjects: 60
Study 24035957 — intervention group
Group type: COMPARATOR
Intervention: Placebo with methadone (40-120 mg)
Number of subjects: 60
Study 21707911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice-daily for 6 weeks
Number of subjects: 91
Study 21707911 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily for 6 weeks
Number of subjects: 91
Study 21707911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 91
Study 21707911 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 91
Study 19149126 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisc
Number of subjects: 147
Study 19149126 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat
Number of subjects: 147
Study 19149126 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat + Provisc
Number of subjects: 147
Study 17135812 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource Use Inventory (RUI) administered at home or in clinic
Number of subjects: 644
Study 17135812 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource Use Inventory (RUI) administered with help of study partners
Number of subjects: 644
Study 17135812 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource Use Inventory (RUI)
Number of subjects: 644
Study 17135812 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based completion of the RUI
Number of subjects: 644
Study 12946338 — intervention group
Group type: COMPARATOR
Intervention: Routine 20‐minute period of Electronic Fetal Monitoring (EFM) at the time of admission (control group)
Number of subjects: 0
Study 12946338 — intervention group
Group type: EXPERIMENTAL
Intervention: No routine admission EFM (study group)
Number of subjects: 0
Study 10674594 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol (E2) 50 microg/day for 14 weeks
Number of subjects: 40
Study 10674594 — intervention group
Group type: COMPARATOR
Intervention: Identical transdermal placebo patches
Number of subjects: 40
Study 8681562 — intervention group
Group type: EXPERIMENTAL
Intervention: Household cleaning products (proprietary products)
Number of subjects: 0
Study 8681562 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneosurfametry test
Number of subjects: 0
Study 1407642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 gm single preoperative dose)
Number of subjects: 86
Study 1407642 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (3 gm daily for one week post-surgery)
Number of subjects: 86
Study 2873010 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 10
Study 2873010 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lormetazepam
Number of subjects: 10
Study 2873010 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 10
Study 2873010 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg flunitrazepam
Number of subjects: 10
Study 2873010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31009765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered oxytocin (OT)
Number of subjects: 46
Study 31009765 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 46
Study 28867335 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring home BP (SMHBP) follow-up with BP target <135/85mmHg
Number of subjects: 116
Study 28867335 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up with clinic BP target <140/90mmHg
Number of subjects: 116
Study 28867335 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study 26775631 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin (100 mg dose)
Number of subjects: 449
Study 26775631 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 449
Study 25139487 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical erythromycin (two applications of 800 mg)
Number of subjects: 16
Study 25139487 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (250 mg)
Number of subjects: 16
Study 25139487 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (1000 mg)
Number of subjects: 16
Study 25139487 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin AUC∞
Number of subjects: 16
Study 22518819 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical-Social Functioning
Number of subjects: 0
Study 22518819 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Functioning
Number of subjects: 0
Study 19083149 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecolic duodenojejunostomy (n = 17)
Number of subjects: 35
Study 19083149 — intervention group
Group type: COMPARATOR
Intervention: Vertical retrocolic duodenojejunostomy (n = 18)
Number of subjects: 35
Study 19083149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (antecolic and vertical retrocolic)
Number of subjects: 35
Study 17993095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol infused at a rate of 3 to 4 mg kg(‐1) h(‐1) (Group A)
Number of subjects: 20
Study 17993095 — intervention group
Group type: COMPARATOR
Intervention: No sedation (Group B)
Number of subjects: 20
Study 17993095 — intervention group
Group type: COMPARATOR
Intervention: Theoretical reference values for plasma melatonin levels (Group D)
Number of subjects: 20
Study 16341745 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex pharmaceutical care intervention by pharmacists
Number of subjects: 185
Study 16341745 — intervention group
Group type: EXPERIMENTAL
Intervention: Final consultation by pharmacists
Number of subjects: 185
Study 14980069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 62
Study 14980069 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 62
Study 14980069 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy Volunteers)
Number of subjects: 62
Study 10444604 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25LT
Number of subjects: 10
Study 10444604 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75LT
Number of subjects: 10
Study 10444604 — intervention group
Group type: EXPERIMENTAL
Intervention: LT
Number of subjects: 10
Study 10444604 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25LT
Number of subjects: 10
Study 10444604 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.75LT
Number of subjects: 10
Study 10444604 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 10
Study 8925656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (15 mg/kg/day titrated to maximum tolerated dose up to 35 mg/kg/day)
Number of subjects: 299
Study 8925656 — intervention group
Group type: COMPARATOR
Intervention: Placebo (titrated similarly to maintain blinding)
Number of subjects: 299
Study 2035570 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electronic fetal heart monitoring
Number of subjects: 0
Study 2035570 — intervention group
Group type: COMPARATOR
Intervention: Auscultation at specified intervals
Number of subjects: 0
Study 2035570 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal heart rate deviations
Number of subjects: 0
Study 2035570 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor and delivery variables (duration of labor, failure to progress, fetal scalp pH values, presence of meconium)
Number of subjects: 0